<DOC>
	<DOC>NCT01497002</DOC>
	<brief_summary>Improvement of the treatment-results in elderly patients with acute myeloid leukemia through intensification of consolidation chemotherapy and/or allografting as consolidative immunotherapy</brief_summary>
	<brief_title>Comparison of the OSHO Protocol to a Standard Arm Protocol of the German AML Intergroup in Patients With AML&gt;60a</brief_title>
	<detailed_description />
	<mesh_term>Leukemia, Myeloid, Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<criteria>Patients of both sexes with age &gt; 60 years and newly diagnosed acute myeloid leukaemia as defined by new WHO classification written informed consent pretreatment of leukemia no informed consent simultaneous inclusion in other studies mental disability contraindication for intensive chemotherapy AML FAB M3 contraindication for allogeneic stem cell transplantation restriction of following organ functions: creatinineclearance &lt; 50 ml/min cardiac ejection fraction &lt; 40 % severe pulmonary restriction bilirubin &gt; 2x ULN; SGOT and SGPT &gt; 4x ULN uncontrolled hypertension severe uncontrolled metabolism disturbance Karnofskyperformancescore &lt; 70% hepatitis C other malignancy age of unrelated donor &gt;70 years and age of related donor &gt;75 years</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>AML</keyword>
</DOC>